Beug ST, Tang VA, LaCasse EC, Cheung HH, Beauregard CE, Brun J, Nuyens JP, Earl N, St-Jean M, Holbrook J et al (2014) Smac mimetics and innate immune stimuli synergize to promote tumor death. Nat Biotechnol 32:182–190PubMed

Bharatan NS, Currier MA, Cripe TP (2002) Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex viruses. J Pediatr Hematol Oncol 24:447–453PubMed

Bid HK, Zhan J, Phelps DA, Kurmasheva RT, Houghton PJ (2012) Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2. Mol Cancer Ther 11:649–659PubMedCentralPubMed

Bid HK, London CA, Gao J, Zhong H, Hollingsworth RE, Fernandez S, Mo X, Houghton PJ (2013) Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy. Clin Cancer Res Off J Am Assoc Cancer Res 19:2984–2994

Bid HK, Roberts RD, Cam M, Audino A, Kurmasheva RT, Lin J, Houghton PJ, Cam H (2014) DeltaNp63 promotes pediatric neuroblastoma and osteosarcoma by regulating tumor angiogenesis. Cancer Res 74:320–329PubMedCentralPubMed

Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4:335–348PubMed

Bostedt KT, Schmid C, Ghirlanda-Keller C, Olie R, Winterhalter KH, Zapf J (2001) Insulin-like growth factor (IGF) I down-regulates type 1 IGF receptor (IGF 1R) and reduces the IGF I response in A549 non-small-cell lung cancer and Saos-2/B-10 osteoblastic osteosarcoma cells. Exp Cell Res 271:368–377PubMed

Braczkowski R, Schally AV, Plonowski A, Varga JL, Groot K, Krupa M, Armatis P (2002) Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like growth factor II. Cancer 95:1735–1745PubMed

Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J et al (2011) Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19:664–678PubMedCentralPubMed

Brenner JC, Feng FY, Han S, Patel S, Goyal SV, Bou-Maroun LM, Liu M, Lonigro R, Prensner JR, Tomlins SA, Chinnaiyan AM (2012) PARP-1 inhibition as a targeted strategy to treat Ewing’s sarcoma. Cancer Res 72:1608–1613PubMedCentralPubMed

Buddingh EP, Schilham MW, Ruslan SE, Berghuis D, Szuhai K, Suurmond J, Taminiau AH, Gelderblom H, Egeler RM, Serra M et al (2011) Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunol Immunother 60:575–586PubMedCentralPubMed

Burke JM, Ahern C, Weigel B, Poirier J, Rudin C, Chen Y, Cripe TP, Bernhardt M, Blaney SM (2015) Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children’s Oncology Group. Pediatr Blood Cancer 62:743–750PubMed

Carter PJ, Senter PD (2008) Antibody-drug conjugates for cancer therapy. Cancer J 14:154–169PubMed

Casanova M, Ferrari A, Spreafico F, Terenziani M, Massimino M, Luksch R, Cefalo G, Polastri D, Marcon I, Bellani FF (2002) Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma. Cancer 94:3263–3268PubMed

Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D’Amato GZ, Blay JY, Mita MM, Sankhala KK, Berk L et al (2012) Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol Off J Am Soc Clin Oncol 30:78–84

Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, Campana D (2010) Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 16:3901–3909PubMedCentralPubMed

Choy E, Butrynski JE, Harmon D et al (2013) Translation of preclinical predictive sensitivity of Ewing sarcoma to PARP inhibition: phase II study of olaparib in adult patients with recurrent/metastatic Ewing sarcoma following failure of prior chemotherapy. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research Abstr #LB-174

Chung JS, Dougherty I, Cruz PD Jr, Ariizumi K (2007a) Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation. J Immunol 179:5778–5784PubMed

Chung JS, Sato K, Dougherty II, Cruz PD Jr, Ariizumi K (2007b) DC-HIL is a negative regulator of T lymphocyte activation. Blood 109:4320–4327PubMedCentralPubMed

Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS, Moyer JD (2005) Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11:2063–2073PubMed

Coley WB (1933) The treatment of sarcoma of the long bones. Ann Surg 97:434–460PubMedCentralPubMed

Cripe TP, Ngo MC, Geller JI, Louis CU, Currier MA, Racadio JM, Towbin AJ, Rooney DM, Pelusio A, Moon A et al (2015) Phase I study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients. Mol Ther 23:602–608PubMed

Currier MA, Eshun FK, Sholl A, Chernoguz A, Crawford K, Divanovic S, Boon L, Goins WF, Frischer JS, Collins MH et al (2013) VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells. Mol Ther 21:1014–1023PubMedCentralPubMed

Darnell JE Jr (2002) Transcription factors as targets for cancer therapy. Nat Rev Cancer 2:740–749PubMed

de Alava E, Panizo A, Antonescu CR, Huvos AG, Pardo-Mindan FJ, Barr FG, Ladanyi M (2000) Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing’s sarcoma. Am J Pathol 156:849–855PubMedCentralPubMed

De Bono JS, Mina LA, Gonzalez M, Curtin NJ, Wang E, Henshaw JW, Chadha M, Sachdev JC, Matei D, Jameson GS et al (2013) First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. J Clin Oncol 31 (Suppl):abstr 2580

Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G et al (1992) Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359:162–165PubMed

Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoel MJ, Fartoux L, Venot C, Bladt F, Housset C, Rosmorduc O (2009) Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res 15:5445–5456PubMed

Dilling MB, Dias P, Shapiro DN, Germain GS, Johnson RK, Houghton PJ (1994) Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res 54:903–907PubMed

Dobrynin P, Matyunina E, Malov SV, Kozlov AP (2013) The novelty of human cancer/testis antigen encoding genes in evolution. Int J Genom 2013:105108

DuBois SG, Krailo MD, Lessnick SL, Smith R, Chen Z, Marina N, Grier HE, Stegmaier K, and Children’s Oncology (2009) Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer 52:324–327

Ebb D, Meyers P, Grier H, Bernstein M, Gorlick R, Lipshultz SE, Krailo M, Devidas M, Barkauskas DA, Siegal GP et al (2012) Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the Children’s Oncology Group. J Clin Oncol 30:2545–2551PubMedCentralPubMed

Edmonson JH, Green SJ, Ivins JC, Gilchrist GS, Creagan ET, Pritchard DJ, Smithson WA, Dahlin DC, Taylor WF (1984) A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma. J Clin Oncol 2:152–156PubMed

Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J (1987) Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 5:21–26PubMed

Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L, Abaan OD, Chou TH, Dakshanamurthy S, Brown ML et al (2009) A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing’s sarcoma. Nat Med 15:750–756PubMedCentralPubMed

Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN (2002) Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 62:7291–7297PubMed

Ferrari S, Palmerini E (2007) Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 19:341–346PubMed

Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C et al (2010) Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28:2512–2519PubMed

Fouladi M, Laningham F, Wu J, O’Shaughnessy MA, Molina K, Broniscer A, Spunt SL, Luckett I, Stewart CF, Houghton PJ et al (2007) Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol Off J Am Soc Clin Oncol 25:4806–4812

Friedman GK, Pressey JG, Reddy AT, Markert JM, Gillespie GY (2009) Herpes simplex virus oncolytic therapy for pediatric malignancies. Mol Ther 17:1125–1135PubMedCentralPubMed

Gable KL, Maddux BA, Penaranda C, Zavodovskaya M, Campbell MJ, Lobo M, Robinson L, Schow S, Kerner JA, Goldfine ID, Youngren JF (2006) Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth. Mol Cancer Ther 5:1079–1086PubMed

Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, Nevala WK, Thompson MA, Lewis JE, Rumilla KM et al (2012) Phase II trial of intravenous administration of Reolysin((R)) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther 20:1998–2003PubMedCentralPubMed

Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J et al (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483:570–575PubMedCentralPubMed

Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, Desjardins C, Fang F, Jansen M, Shuster DE et al (2009) A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res Off J Am Assoc Cancer Res 15:4207–4212

Goetsch L, Gonzalez A, Leger O, Beck A, Pauwels PJ, Haeuw JF, Corvaia N (2005) A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 113:316–328PubMed

Gollamudi R, Ghalib MH, Desai KK, Chaudhary I, Wong B, Einstein M, Coffey M, Gill GM, Mettinger K, Mariadason JM et al (2010) Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs 28:641–649PubMed

Gorlick R, Maris JM, Houghton PJ, Lock R, Carol H, Kurmasheva RT, Kolb EA, Keir ST, Reynolds CP, Kang MH et al (2012) Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 59:518–524PubMedCentralPubMed

Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen QR, Yeung C, Currier DG, Davis S, Khanna C, Khan J et al (2011) Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J Natl Cancer Inst 103:962–978PubMedCentralPubMed

Guerreiro AS, Boller D, Doepfner KT, Arcaro A (2006) IGF-IR: potential role in antitumor agents. Drug News Perspect 19:261–272PubMed

Guertin DA, Sabatini DM (2009) The pharmacology of mTOR inhibition. Sci Signal 2:pe24PubMed

Guse K, Cerullo V, Hemminki A (2011) Oncolytic vaccinia virus for the treatment of cancer. Expert Opin Biol Ther 11:595–608PubMed

Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG, Frennesson DB, Kalli KR, Conover CA, Attar RM et al (2006) In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res 66:362–371PubMed

Hammill AM, Conner J, Cripe TP (2010) Oncolytic virotherapy reaches adolescence. Pediatr Blood Cancer 55:1253–1263PubMed

Han EQ, Li XL, Wang CR, Li TF, Han SY (2013) Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. J Hematol Oncol 6:47PubMedCentralPubMed

Himoudi N, Wallace R, Parsley KL, Gilmour K, Barrie AU, Howe K, Dong R, Sebire NJ, Michalski A, Thrasher AJ, Anderson J (2012) Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma. Clin Transl Oncol 14:271–279PubMed

Hingorani P, Zhang W, Lin J, Liu L, Guha C, Kolb EA (2011) Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts. Cancer 117:1764–1774PubMed

Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, Maher CA, Panji S, Schaefer U, Kruger A et al (2008) Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A 105:20422–20427PubMedCentralPubMed

Hong SH, Youbi SE, Hong SP, Kallakury B, Monroe P, Erkizan HV, Barber-Rotenberg JS, Houghton P, Uren A, Toretsky JA (2014) Pharmacokinetic modeling optimizes inhibition of the ‘undruggable’ EWS-FLI1 transcription factor in Ewing Sarcoma. Oncotarget 5:338–350PubMedCentralPubMed

Horton JK, Wilson SH (2013) Predicting enhanced cell killing through PARP inhibition. Mol Cancer Res 11:13–18PubMedCentralPubMed

Houchens DP, Ovejera AA, Riblet SM, Slagel DE (1983) Human brain tumor xenografts in nude mice as a chemotherapy model. Eur J Cancer Clin Oncol 19:799–805PubMed

Houghton PJ, Morton CL, Kolb EA, Gorlick R, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA (2008) Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 50:799–805PubMed

Houghton PJ, Morton CL, Gorlick R, Lock RB, Carol H, Reynolds CP, Kang MH, Maris JM, Keir ST, Kolb EA et al (2010a) Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Ther 9:101–112PubMedCentralPubMed

Houghton PJ, Morton CL, Kang M, Reynolds CP, Billups CA, Favours E, Payne-Turner D, Tucker C, Smith MA (2010b) Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program. Pediatr Blood Cancer 55:1224–1226PubMed

Hromas R, Klemsz M (1994) The ETS oncogene family in development, proliferation and neoplasia. Int J Hematol 59:257–265PubMed

Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM, Reeves K, Chen J, Robinson D, Li A et al (2009) The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 69:161–170PubMed